Applied Therapeutics Inc Corporate Update Call Transcript
Welcome to Applied Therapeutics' SORD Deficiency Interim Data Conference Call. I would now like to turn the conference over to Dr. Shoshana Shendelman, Applied Therapeutics' Founder and CEO. Please go ahead.
Welcome, everyone, and thank you for joining us on today's call. With me on the call are Dr. Riccardo Perfetti, our Chief Medical Officer; Adam Hansard, our Chief Commercial Officer; and Dr. Michael Shy, Director of the Division of Neuromuscular Medicine at Carver College of Medicine, University of Iowa, and one of the original researchers responsible for identifying the genetic and pathophysiological cause of SORD deficiency. Dr. Shy is also the Principal Investigator on the INSPIRE Phase 3 trial.
Before we begin, let me remind you that today's conference call will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events. These forward-looking statements are qualified by important factors set forth in today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |